Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.
Also called NCT06421870
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT06421870
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Unknown status
Technical summary
Registry record NCT06421870. Randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Drug)
- Pentoxifylline 400 MG
- Lead sponsor
- Ain Shams University
Record details
- Record id
cardio:ct-nct06421870- Content hash
5c9301736c3fc8c6f768e24158e64f8781b1f5061ba47faaf25b8c9665562f60